lung cancer (metastatic)

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

ALK inhibitors

alectinib
ALUR, 2018    NCTalectinibchemotherapy2L 2nd line crizotinib failure Exploratory -
ALEX, 2017      NCTalectinibcrizotinib1L 1st line Risk of bias -
ceritinib
ASCEND-4, 2017      NCTceritinibchemotherapy1L 1st line nonsquamous NSCLC Risk of bias -
ASCEND 5, 2017      NCTceritinibpemetrexed or docetaxel2L after crizotinib failure 2nd line crizotinib failure -
crizotinib
Shaw, 2013      NCTcrizotinibchemotherapy2L 2nd line Risk of bias -
PROFILE 1014, 2014        NCTcrizotinibchemotherapy1L 1st line nonsquamous NSCLC Risk of bias -

angiogenesis inhibitors

not classified
Hanna, 2013   -
Heymach, 2008      -
Reck, 2014      NCTDocetaxel plus nintedanib docetaxel plus placebo Low risk of bias -
aflibercept
Ramlau, 2012     Aflibercept and Docetaxel Docetaxel Low risk of bias -
bevacizumab
Reck, 2010     bevacizumab -
Herbst, 2011     bevacizumab + erlotiniberlotinib alone -
Sandler, 2006     bevacizumabplatinum based CT -
Johnson, 2004     bevacizumabplatinum based CT -
Nishio, 2009   bevacizumabplatinum based CT -
Herbst, 2007     bevacizumabplatinum based CT -
ceritinib
Laurie, 2014     cediranib carboplatin and paclitaxel -
Goss, 2010     cediranib carboplatin and paclitaxel -
Dy, 2013     cediranib gemcitabine and carboplatin -
docetaxel
REVEL, 2014      NCTramucirumab + docetaxeldocetaxel aloneLow risk of bias -
motesanib
Scagliottib MONET1, 2012     motesanib plus carboplatin/paclitaxel -
pazopanib
Scagliotti, 2013     pazopanib pemetrexed -
sorafenib
Wakelee, 2012     sorafenib -
Paz-Ares, 2012     sorafenib -
Spigel, 2011     sorafenib and erlotinib erlotinib -
Scagliotti, 2010     sorafenibplacebo -
sunitinib
Groen, 2013     sunitinib erlotinib Low risk of bias -
Scagliottia, 2012     Sunitinib plus erlotinib erlotinib -
Heist CALGB 30704 (Alliance): , 2014     sunitinib pemetrexed -
vandetanib
Aisner, 2013     vandetanib -
Ahn, 2013     vandetanib maintenance -
de Boer, 2011     Vandetanib plus pemetrexed -
Natale, 2009     Vandetanib versus gefitinib Low risk of bias -
Natale, 2011     Vandetanib gefitinib Low risk of bias -
Lee ZEPHYR, 2012     Vandetanib placebo -
Heymach, 2007      vandetanib plus docetaxel placebo plus docetaxel -

CDK (cyclin-dependent kinase) inhibitor

abemaciclib
JUNIPER, 2018      NCTabemacicliberlotinib2nd lineRisk of bias remark

chemotherapy

not classified
Scagliotti (pemetrexed vs bortezomib), 2010     pemetrexedbortezomib -
Scagliotti, 2010     bortezomib and pemetrexedpemetrexed -
Chiappori, 2010   enzastaurin plus pemetrexedpemetrexed -
Schiller, 2010   matuzumab plus pemetrexedpemetrexed -
pemetrexed
Chen, 2008   pemetrexeddocetaxel -
Hanna, 2004     pemetrexeddocetaxel -
Li, 2012     pemetrexeddocetaxel -
Sun, 2013      NCTpemetrexeddocetaxel -
Jose, 2011     pemetrexed plus carboplatindocetaxel plus carboplatin -
Socinski, 2010      NCTpemetrexed plus carboplatindocetaxel plus carboplatin -
Smit, 2009   pemetrexed plus carboplatinpemetrexed -
vandetanib
De Boer, 2011     vandetanib plus pemetrexedpemetrexed -

EGFR inhibitors

not classified
SQUIRE    NCT -
INSPIRE    NCT -
afatinib
LUX-LUNG 3, 2015         afatinibcisplatin-based chemotherapy -
LUX-LUNG 6, 2015       afatinibcisplatin-based chemotherapy -
cetuximab
Lynch, 2010     cetuximabCTRisk of bias -
Butts, 2007     cetuximabCT alone -
FLEX (Pirker), 2009      NCTcetuximab + CTCT alone -
Rosell, 2008     cetuximab + CTCT alone -
dacomitinib
ARCHER 1050      NCTdacomitinibgefitinib -
erlotinib
OPTIMAL     erlotinibPlatinum-based CT EGFR mutations Risk of bias -
EUTRAC     erlotinibPlatinum-based CT 1st line EGFR mutations Risk of bias -
TITAN       erlotinibPlatinum-based CT 2nd line Risk of bias -
TRIBUTE (Herbst)     erlotinib + Platinum-based CTPlatinum-based CT 1st line -
Gatzemeier     erlotinib + Platinum-based CTPlatinum-based CT 1st line -
Mok     erlotinib + Platinum-based CTPlatinum-based CT 1st line -
SATURN (Cappuzzo)     erlotinib + Platinum-based CTPlatinum-based CT maintenance therapy -
Boutsikou     erlotinib + Platinum-based CTPlatinum-based CT 1st line -
Lee     erlotinib + Platinum-based CTPlatinum-based CT 2nd line -
Stinchcombe   erlotinib + Platinum-based CTPlatinum-based CT -
FASTACT-2 (Wu)     erlotinib + Platinum-based CTPlatinum-based CT 1st line -
gefitinib
West Japan   gefitinib -
Northeast Japan   gefitinib -
CTONG0806 (Yang), 2013   gefitinib -
NEJ002, 2013     gefitinibcarboplatin-paclitaxel1L -
Maemondo, 2010       gefitinibcarboplatin-paclitaxel2L -
IPASS (Mok), 2009      NCTgefitinibcarboplatin-paclitaxel1L -
IPASS           gefitinibcarboplatin/paclitaxel1L -
WJTOG3405 (Mitsudomi), 2010     gefitinibcisplatin plus docetaxel -
WJTOG0203 (Takeda), 2010     gefitinibcontinued platinum-doublet chemotherapy -
ISTANA (Lee), 2010     gefitinibdocetaxel2L -
V-15-32 (Maruyama), 2008         gefitinibdocetaxel2L -
INTEREST (Kim), 2008   gefitinibdocetaxel2L -
SIGN (Cufer), 2006   gefitinibdocetaxel2L -
IFCT-0301 study (Morère), 2010     gefitinibdocetaxel -
Kris, 2003     gefitinibgefitinib2LLow risk of bias -
First Signal       gefitinibgemcitabine and cisplatin1L -
INTACT 2, 2004     gefitinib paclitaxel and carboplatinpaclitaxel and carboplatin1LLow risk of bias -
NCIC CTG BR19 (Goss), 2013     gefitinibplaceboLow risk of bias -
INFORM; C-TONG 0804, 2012      NCTgefitinibplacebo -
EORTC 08021/ILCP 01/03, 2011      NCTgefitinibplacebo2L -
Goss, 2009     gefitinibplacebo1L -
SWOG S0023 (Kelly), 2008     gefitinibplacebo -
ISEL, 2006       gefitinibplacebo2L -
Tsuboi, 2005     gefitinibplacebo -
INTACT 1.     gefitinib + gemcitabine/cisplatinplacebo + gemcitabine / cisplatin1LLow risk of bias -
INVITE (Crinò), 2008      NCTgefitinibvinorelbine1L -
osimertinib
FLAURA, 2017      NCTosimertinibplacebo1LLow risk of bias -
AURA 3, 2017    NCTosimertinibplatinum-based therapy plus pemetrexed 2L -

immune checkpoint inhibition

atezolizumab
IMpower150 (WT), 2018      NCTatezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L 1st line nonsquamous NSCLC Risk of bias -
IMpower150 (Teff), 2018        NCTatezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L, Teff 1st line nonsquamous NSCLC Risk of bias -
POPLAR Phase 2 atezolizumab, 2016    NCTatezolizumabdocetaxel2L 2nd+ line platinum failure Risk of bias -
OAK, 2016      NCTatezolizumabdocetaxel2L 2nd+ line platinum failure Risk of bias -
durvalumab
PACIFIC, 2017      NCTdurvalumabplacebomaintenance maintenance therapy Low risk of bias -
ARCTIC PD-L1 negative, 2018    NCTdurvalumab + tremelimumabStandard of Care3L, PD-L1 negative -
ipilimumab
Reck, 2016      NCTipilimumab + chemotherapyplacebo + chemotherapySCLCLow risk of bias -
Govindan, 2017      NCTipilimumab + chemotherapyplacebo + chemotherapy1LLow risk of bias -
phase 2 (phased ipilimumab), 2012     ipilimumab + chemotherapyplacebo + chemotherapyLow risk of bias -
nivolumab
CheckMate 057, 2015      NCTnivolumabdocetaxel2L, non squamous 2nd+ line nonsquamous NSCLC Risk of bias -
CheckMate 017, 2015    NCTnivolumabdocetaxel2L, squamous 2nd+ line squamous NSCLC Risk of bias -
CheckMate 026, 2016    NCTnivolumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias remark
CheckMate 227 (nivolumab + CT), 2018    NCTnivolumab + CTplatinum-based CT1L, PDL1 negatif 1st line PD-L1 negatif -
CheckMate 227 (High Tumor Mutational Burden), 2018      NCTnivolumab + ipilimumabplatinum-based CT1L, hi TMB 1st line Risk of bias -
pembrolizumab
Keynote 010 10mg, 2015      NCTpembrolizumab 10mgdocetaxel2L, PD-L1 positive 2nd+ line Risk of bias -
Keynote 010 2mg, 2015      NCTpembrolizumab 2mgdocetaxel2L, PD-L1 positive 2nd+ line Risk of bias -
Keynote 042 (>=1%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias remark
Keynote 024, 2015      NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias -
Keynote 042 (>=50%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias -
Keynote 042 (>=20%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias -
KEYNOTE-021 phase 2, 2016      NCTpembrolizumab + platinum-based CTplatinum-based CT1L nonsquamous 1st line nonsquamous NSCLC Exploratory -
Keynote 189, 2018      NCTpembrolizumab + platinum-based CTplatinum-based CT1L PD-L1 positive nonsquamous 1st line nonsquamous NSCLC Low risk of bias -
Keynote 407, 2018    NCTpembrolizumanb + CTplatinum-based CT1L squamous squamous NSCLC Risk of bias -

Taxanes

not classified
Herbst      -
Gebbia      -
Pectasides      -
Takeda      -
Pallis      -
Heymach      -
Wachters      -
Segawa   -
TAX 320 75mg/m2, 2000     docetaxel D75 -
TAX 317 (Shepherd) 75mg/m2, 2000     docetaxel D75 -
docetaxel
TAX 317 (Shepherd) 100mg/m2, 2000       docetaxel -
TAX 320 100mg/m2, 2000     docetaxel -
DISTAl 01 (Gridelli) , 2004     weekly docetaxel3-weekly docetaxel -
Camps     weekly docetaxel3-weekly docetaxel -
Schuette     weekly docetaxel3-weekly docetaxel -
Gervais     weekly docetaxel3-weekly docetaxel -
Lai     weekly docetaxel3-weekly docetaxel -
Chen     weekly docetaxel3-weekly docetaxel -
Esteban, 2003     paclitaxel 80mg/m2m2docetaxel 36 mg/ -